Statins have immunomodulatory effects on Th17-mediated human autoimmune response in multiple sclerosis by selectively inhibiting IL-17 transcription and IL-17A, IL-17F, and IL-22 secretion in Th17 cells, and by suppressing Th17-polarizing cytokine release by dendritic cells.28‐30 However, little is known about these immunomodulatory effects of statins in patients with COPD. This evidence concerns the gene IL22 and multiple sclerosis.